BACKGROUND: Risk stratification of newly diagnosed patients with mantle cell lymphoma (MCL) primarily is based on the MCL International Prognostic Index (MIPI) and Ki-67 proliferative index. Single-center studies have reported inferior outcomes in patients with a complex karyotype (CK), but this remains an area of controversy. METHODS: The authors retrospectively reviewed 483 patients from 5 academic centers in the United States and described the effect of a CK on survival outcomes in individuals with MCL. RESULTS: A CK was found to be associated with inferior overall survival (OS) (4.5 vs 11.6 years; P<.01) and progression-free survival (PFS) (1.9 vs 4.4 years; P<.01). In patients who underwent high-intensity induction followed by autologous stem cell transplantation (ASCT) in first remission, a CK was associated with poor OS (5.1 vs 11.6 years; P = .04) and PFS (3.6 vs 7.8 years; P<.01). Among patients with a CK, high-intensity induction had no effect on OS (4.5 vs 3.8 years; P = .77) nor PFS (2.3 vs 1.5 years; P = .46). Similarly, ASCT in first remission did not improve PFS (3.5 vs 1.2 years; P = .12) nor OS (5.1 vs 4.0 years; P = .27). On multivariable analyses with Ki-67 and MIPI, only CK was found to be predictive of OS (hazard ratio [HR], 1.98; 95% confidence interval [95% CI], 1.12-3.49 [P = .02]), whereas both CK (HR, 1.91; 95% CI, 1.17-3.12 [P = .01]) and Ki-67 >30% (HR, 1.86; 95% CI, 1.06-3.28 [P = .03]) were associated with inferior PFS. Multivariable analysis did not identify any specific cytogenetic abnormalities associated with inferior survival. CONCLUSIONS: CK appears to be independently associated with inferior outcomes in patients with MCL regardless of the intensity of induction therapy and receipt of ASCT. Cytogenetics should be incorporated into the workup of a new diagnosis of MCL and novel therapeutic approaches should be investigated for patients with CK. Cancer 2018;124:2306-15.
BACKGROUND: Risk stratification of newly diagnosed patients with mantle cell lymphoma (MCL) primarily is based on the MCL International Prognostic Index (MIPI) and Ki-67 proliferative index. Single-center studies have reported inferior outcomes in patients with a complex karyotype (CK), but this remains an area of controversy. METHODS: The authors retrospectively reviewed 483 patients from 5 academic centers in the United States and described the effect of a CK on survival outcomes in individuals with MCL. RESULTS: A CK was found to be associated with inferior overall survival (OS) (4.5 vs 11.6 years; P<.01) and progression-free survival (PFS) (1.9 vs 4.4 years; P<.01). In patients who underwent high-intensity induction followed by autologous stem cell transplantation (ASCT) in first remission, a CK was associated with poor OS (5.1 vs 11.6 years; P = .04) and PFS (3.6 vs 7.8 years; P<.01). Among patients with a CK, high-intensity induction had no effect on OS (4.5 vs 3.8 years; P = .77) nor PFS (2.3 vs 1.5 years; P = .46). Similarly, ASCT in first remission did not improve PFS (3.5 vs 1.2 years; P = .12) nor OS (5.1 vs 4.0 years; P = .27). On multivariable analyses with Ki-67 and MIPI, only CK was found to be predictive of OS (hazard ratio [HR], 1.98; 95% confidence interval [95% CI], 1.12-3.49 [P = .02]), whereas both CK (HR, 1.91; 95% CI, 1.17-3.12 [P = .01]) and Ki-67 >30% (HR, 1.86; 95% CI, 1.06-3.28 [P = .03]) were associated with inferior PFS. Multivariable analysis did not identify any specific cytogenetic abnormalities associated with inferior survival. CONCLUSIONS:CK appears to be independently associated with inferior outcomes in patients with MCL regardless of the intensity of induction therapy and receipt of ASCT. Cytogenetics should be incorporated into the workup of a new diagnosis of MCL and novel therapeutic approaches should be investigated for patients with CK. Cancer 2018;124:2306-15.
Authors: Jenny Zhang; Dereje Jima; Andrea B Moffitt; Qingquan Liu; Magdalena Czader; Eric D Hsi; Yuri Fedoriw; Cherie H Dunphy; Kristy L Richards; Javed I Gill; Zhen Sun; Cassandra Love; Paula Scotland; Eric Lock; Shawn Levy; David S Hsu; David Dunson; Sandeep S Dave Journal: Blood Date: 2014-03-28 Impact factor: 22.113
Authors: Jonathon B Cohen; Amy S Ruppert; Nyla A Heerema; Leslie A Andritsos; Jeffrey A Jones; Pierluigi Porcu; Robert Baiocchi; Beth A Christian; John C Byrd; Joseph Flynn; Sam Penza; Steven M Devine; Kristie A Blum Journal: Clin Lymphoma Myeloma Leuk Date: 2014-12-31
Authors: A Cuneo; R Bigoni; G M Rigolin; M G Roberti; A Bardi; N Piva; R Milani; F Bullrich; M L Veronese; C Croce; F Birg; H Döhner; A Hagemeijer; G Castoldi Journal: Blood Date: 1999-02-15 Impact factor: 22.113
Authors: Lihua E Budde; Katherine A Guthrie; Brian G Till; Oliver W Press; Thomas R Chauncey; John M Pagel; Steven H Petersdorf; William I Bensinger; Leona A Holmberg; Andrei R Shustov; Damian J Green; David G Maloney; Ajay K Gopal Journal: J Clin Oncol Date: 2011-07-05 Impact factor: 44.544
Authors: Eva Hoster; Andreas Rosenwald; Françoise Berger; Heinz-Wolfram Bernd; Sylvia Hartmann; Christoph Loddenkemper; Thomas F E Barth; Nicole Brousse; Stefano Pileri; Grzegorz Rymkiewicz; Roman Kodet; Stephan Stilgenbauer; Roswitha Forstpointner; Catherine Thieblemont; Michael Hallek; Bertrand Coiffier; Ursula Vehling-Kaiser; Réda Bouabdallah; Lothar Kanz; Michael Pfreundschuh; Christian Schmidt; Vincent Ribrag; Wolfgang Hiddemann; Michael Unterhalt; Johanna C Kluin-Nelemans; Olivier Hermine; Martin H Dreyling; Wolfram Klapper Journal: J Clin Oncol Date: 2016-02-29 Impact factor: 44.544
Authors: Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt Journal: Blood Date: 2007-10-25 Impact factor: 22.113
Authors: Lena Nordström; Sandra Sernbo; Patrik Eden; Kirsten Grønbaek; Arne Kolstad; Riikka Räty; Marja-Liisa Karjalainen; Christian Geisler; Elisabeth Ralfkiaer; Christer Sundström; Anna Laurell; Jan Delabie; Mats Ehinger; Mats Jerkeman; Sara Ek Journal: Br J Haematol Date: 2014-03-29 Impact factor: 6.998
Authors: Sílvia Beà; Rafael Valdés-Mas; Alba Navarro; Itziar Salaverria; David Martín-Garcia; Pedro Jares; Eva Giné; Magda Pinyol; Cristina Royo; Ferran Nadeu; Laura Conde; Manel Juan; Guillem Clot; Pedro Vizán; Luciano Di Croce; Diana A Puente; Mónica López-Guerra; Alexandra Moros; Gael Roue; Marta Aymerich; Neus Villamor; Lluís Colomo; Antonio Martínez; Alexandra Valera; José I Martín-Subero; Virginia Amador; Luis Hernández; Maria Rozman; Anna Enjuanes; Pilar Forcada; Ana Muntañola; Elena M Hartmann; María J Calasanz; Andreas Rosenwald; German Ott; Jesús M Hernández-Rivas; Wolfram Klapper; Reiner Siebert; Adrian Wiestner; Wyndham H Wilson; Dolors Colomer; Armando López-Guillermo; Carlos López-Otín; Xose S Puente; Elías Campo Journal: Proc Natl Acad Sci U S A Date: 2013-10-21 Impact factor: 11.205
Authors: David A Bond; Jeffrey M Switchenko; Diego Villa; Kami Maddocks; Michael Churnetski; Alina S Gerrie; Subir Goyal; Krithika Shanmugasundaram; Oscar Calzada; Bhaskar Kolla; Veronika Bachanova; James N Gerson; Stefan K Barta; Brian T Hill; Yazeed Sawalha; Peter Martin; Edward Maldonado; Max Gordon; Alexey V Danilov; Natalie S Grover; Stephanie Mathews; Madelyn Burkart; Reem Karmali; Nilanjan Ghosh; Steven I Park; Narendranath Epperla; Talha Badar; Jin Guo; Mehdi Hamadani; Timothy S Fenske; Mary-Kate Malecek; Brad S Kahl; Christopher R Flowers; Kristie A Blum; Jonathon B Cohen Journal: Blood Adv Date: 2021-12-14
Authors: F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse Journal: Leukemia Date: 2022-04-16 Impact factor: 12.883
Authors: Krithika Shanmugasundaram; Subir Goyal; Jeffery Switchenko; Oscar Calzada; Michael C Churnetski; Bhaskar Kolla; Veronika Bachanova; James N Gerson; Stefan K Barta; Max J Gordon; Alexey V Danilov; Natalie S Grover; Stephanie Mathews; Madelyn Burkart; Reem Karmali; Yazeed Sawalha; Brian T Hill; Nilanjan Ghosh; Steven I Park; Narendranath Epperla; David A Bond; Talha Badar; Kristie A Blum; Mehdi Hamadani; Timothy S Fenske; Mary Malecek; Brad S Kahl; Peter Martin; Jin Guo; Christopher R Flowers; Jonathon B Cohen Journal: Eur J Haematol Date: 2021-06-17 Impact factor: 2.997